41564-60-7

Upstream product

• 75-97-8 3,3-dimethyl-butan-2-one 
• 104-87-0 4-methyl-benzaldehyde 
• 917-92-0 3,3-Dimethylbut-1-yne 
• 27654-03-1 4,4-dimethyl-1-(4-methylphenyl)-2-pentyn-1-ol 

Downstream Products

• 84669-22-7 (E)-4,4-Dimethyl-1-p-tolyl-pent-1-en-3-one O-methyl-oxime 
• 84669-27-2 (E)-4,4-Dimethyl-1-p-tolyl-pent-1-en-3-one O-benzyl-oxime 
• 84669-18-1 1-Aminooxy-4,4-dimethyl-1-p-tolyl-pentan-3-one oxime 
• 1400633-41-1 4-(3-tert-butyl-5-p-tolyl-4,5-dihydro-1H-pyrazol-1-yl)benzoic acid 
• 84669-34-1 Benzaldehyde O-{3-[(Z)-hydroxyimino]-4,4-dimethyl-1-p-tolyl-pentyl}-oxime 

Relevant academic research and scientific papers

From Celecoxib to a Novel Class of Phosphodiesterase 5 Inhibitors: Trisubstituted Pyrazolines as Novel Phosphodiesterase 5 Inhibitors with Extremely High Potency and Phosphodiesterase Isozyme Selectivity

A ligand-based approach involving systematic modifications of a trisubstituted pyrazoline scaffold derived from the COX2 inhibitor, celecoxib, was used to develop novel PDE5 inhibitors. Novel pyrazolines were identified with potent PDE5 inhibitory activit

Discovery of trisubstituted pyrazolines as a novel scaffold for the development of selective phosphodiesterase 5 inhibitors

Celecoxib, is a selective cyclooxygenase-2 (COX2) inhibitor with a 1,5-diaryl pyrazole scaffold. Celecoxib has a better safety profile compared to other COX2 inhibitors having side effects of systemic hypertension and thromboembolic complications. This may be partly attributed to an off-target activity involving phosphodiesterase 5 (PDE5) inhibition and the potentiation of NO/cGMP signalling allowing coronary vasodilation and aortic relaxation. Inspired by the structure of celecoxib, we synthesized a chemically diverse series of compounds containing a 1,3,5-trisubstituted pyrazoline scaffold to improve PDE5 inhibitory potency, while eliminating COX2 inhibitory activity. SAR studies for PDE5 inhibition revealed an essential role for a carboxylic acid functionality at the 1-phenyl and the importance of the non-planar pyrazoline core over the planar pyrazole with the 5-phenyl moiety tolerating a range of substituents. These modifications led to new PDE5 inhibitors with approximately 20-fold improved potency to inhibit PDE5 and no COX-2 inhibitory activity compared with celecoxib. PDE isozyme profiling of compound 11 revealed a favorable selectivity profile. These results suggest that trisubstituted pyrazolines provide a promising scaffold for further chemical optimization to identify novel PDE5 inhibitors with potential for less side effects compared with available PDE5 inhibitors used for the treatment of penile erectile dysfunction and pulmonary hypertension.

Phosphorous acid promoted isomerization of propargyl alcohols to α,β-unsaturated carbonyl compounds

A metal-free and two-phase protocol for the Meyer-Schuster isomerization of propargyl alcohols to the corresponding α,β-unsaturated carbonyl compounds has been achieved in the presence of stoichiometric phosphorous acid aqueous solution, which produces the desired products in high yields with excellent stereoselectivity. Compared with the traditional methods, the procedure features broad scope of the substrates, mild conditions, and easy separation, providing an appealing alternative to the Meyer-Schuster reaction.

Long chain dicationic phase transfer catalysts in the condensation reactions of aromatic aldehydes in water under ultrasonic effect

Long chain dicationic ammonium salts were used successfully as phase transfer catalyst in the condensation reactions of aromatic aldehydes in water under ultrasonic irradiation for the first time. The quaternary salt having longer distance between the cation centers was more effective than the mono- and dicationic ones having short chain.